4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001549595-24-000110
Chief Financial Officer sold 3,477 shares at an average $21.45 ($74,576)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
van Houte Hans · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-08-01 | Sale : show line 1 in the form 10b5-1 | −3,377 | $21.43 | $72,354 | 51,102 | D |
| 2024-08-01 | Sale : show line 2 in the form 10b5-1 | −100 | $22.22 | $2,222 | 51,002 | D |
| Open-market sales · 3,477 sh · avg $21.45 · $74,576 | ||||||
Loading xslF345X05/wk-form4_1722553573.xml…